ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

PRINCETON, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 3:00 p.m. PT / 6:00 p.m. ET.

The live and archived webcast will be accessible from the Company’s website at , under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 30 days.

About ANI

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit .

Investor Relations:

Courtney Mogerley, Argot Partners

E:

Media Relations:

Deborah Elson, Argot Partners

E:



EN
06/01/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ANI Pharmaceuticals Inc.

 PRESS RELEASE

ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 20...

ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities For full year 2025, total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS expected to be within or above guidance ranges of $854 million to $873 million, $221 million to $228 million and $7.37 to $7.64, respectivelyRare Disease business delivered exceptional growth with full year 2025 Purified Cortrophin® Gel net revenues of $347.8 million, up 76% year-over-year, and ILUVIEN and YUTIQ net revenues of $74.9 million, based on preliminary, una...

 PRESS RELEASE

ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthca...

ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference PRINCETON, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 3:00 p.m. PT / 6:00 p.m. ET. The live and archived webcast will be accessible from the Company’s website at , under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 30 days. Abo...

 PRESS RELEASE

ANI Pharmaceuticals Announces Formation of “FutureVision Advisory Coun...

ANI Pharmaceuticals Announces Formation of “FutureVision Advisory Council” to Help Strategically Guide Ophthalmology and Retina Franchise Expert retina and uveitis specialists will help support the growth and innovation of ANI’s ophthalmology and retina franchise for a meaningful impact on patients PRINCETON, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that it has established The FutureVision Advisory Council to help guide the strategic advancement of its ophthalmology and retina franchise within the Company’s...

 PRESS RELEASE

ANI Pharmaceuticals Announces Board Transition

ANI Pharmaceuticals Announces Board Transition Patrick D. Walsh steps down as Chairman and will complete his current term as Board memberThomas J. Haughey has been unanimously elected to serve as the next Chairman of the Board PRINCETON, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that its Chairman, Patrick D. Walsh, will retire from the Company's Board of Directors after a distinguished tenure of service. His retirement will be effective after completing his current term through the Company’s 2026 Annual Meet...

 PRESS RELEASE

ANI Pharmaceuticals to Present at the Piper Sandler 37th Annual Health...

ANI Pharmaceuticals to Present at the Piper Sandler 37th Annual Healthcare Conference PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, at 2:00 p.m. ET. The live and archived fireside chat will be accessible from the Company’s website at , under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 90 da...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch